Compare Revvity Inc (RVTY) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs State Street PDR S&P Retail ETF — how do they compare? Revvity Inc trades at $116 (market cap $12.91B), while State Street PDR S&P Retail ETF trades at $88.84. The key difference: Revvity Inc pays a 0.24% dividend while State Street PDR S&P Retail ETF pays none, and Revvity Inc is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals.
| RVTY | XRT | |
|---|---|---|
Market Cap | $12.91B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $117.75 | $92.35 |
52-Week Low | $82.26 | $77.28 |
Enterprise Value | $15.23B | — |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
XRT trades at $88.81, down 1.96% today, with a bullish technical signal from moving averages and key indicators like ADX suggesting a strong trend. The ETF's valuation metrics are not available in the provided data, but recent news highlights retail sector focus amid mixed economic signals. A dividend of $0.19 is scheduled for June 2026, adding income potential.
The outlook for XRT is cautiously optimistic, driven by positive retail sales trends and potential Fed easing, but risks include consumer sentiment pressures and inflation. Analyst sentiment is mixed, with some downgrades citing macro headwinds, making it essential to monitor economic indicators for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
